Trial Profile
Fecal Microbiota Transplantation Using RBX2660 for the Prevention of Recurrent Urinary Tract Infections Due to Multidrug Resistant Organisms
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Oct 2022
Price :
$35
*
At a glance
- Drugs RBX 2660 (Primary)
- Indications Urinary tract infections
- Focus Adverse reactions
- 11 Oct 2022 According to a Ferring Pharmaceuticals media release, an ad hoc subgroup analysis of efficacy and safety in the trial will be presented at the American College of Gastroenterology Annual Scientific Meeting & Postgraduate Course (ACG) 2022.
- 02 Feb 2022 Status changed from active, no longer recruiting to completed.
- 19 Apr 2021 Planned End Date changed from 30 Jun 2021 to 31 Dec 2021.